Connecting via Winsock to STN

5/20/05 — 10/699,106

Welcome to STN International! Enter x:x

LOGINID:SSSPTAAJP1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

update structure search



incomplete search - too many iterations

7 hits CAPLUS

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:40:22 ON 20 MAY 2005

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:40:29 ON 20 MAY 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2005 HIGHEST RN 850784-62-2
DICTIONARY FILE UPDATES: 19 MAY 2005 HIGHEST RN 850784-62-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10699106\10699106e.str



chain nodes :
6 7 8 9 10 11 12 13
ring nodes :
1 2 3 4 5
chain bonds :
5-7 6-8 6-13 7-8 8-9 10-11 11-12 11-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-7 6-8 6-13 8-9 10-11 11-12 11-13

exact bonds :
7-8

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1
SAMPLE SEARCH INITIATED 13:40:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 34367 TO ITERATE

2.9% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 676264 TO 698416
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s L1 full
FULL SEARCH INITIATED 13:40:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 687320 TO ITERATE

53.7% PROCESSED 368752 ITERATIONS 0 ANSWERS

58.2% PROCESSED 400000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.23

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 687320 TO 687320
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS FUL L1

=> fil reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 163.91 | 164.12

FILE 'REGISTRY' ENTERED AT 13:44:38 ON 20 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2005 HIGHEST RN 850784-62-2
DICTIONARY FILE UPDATES: 19 MAY 2005 HIGHEST RN 850784-62-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* The CA roles and document type information have been removed from the IDE default display format and the ED field has been added, effective March 20, 2005. A new display format, IDERL, is now available and contains the CA role and document type information. *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10699106\10699106f.str



chain nodes :
6 7 8 9 10 11 18
ring nodes :
1 2 3 4 5 12 13 14 15 16 17
chain bonds :

5-7 6-8 6-18 7-8 8-12 9-10 10-11 10-18
ring bonds :
1-2 1-5 2-3 3-4 4-5 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-7 6-8 6-18 9-10 10-11 10-18
exact bonds :
7-8 8-12
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L4   STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4   STR



Structure attributes must be viewed using STN Express query preparation.

=> s L4
SAMPLE SEARCH INITIATED 13:44:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1395 TO ITERATE

 71.7% PROCESSED   1000 ITERATIONS   7 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 25660 TO   30140
PROJECTED ANSWERS: 8 TO   382

L5   7 SEA SSS SAM L4

=> s L4 full
FULL SEARCH INITIATED 13:45:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 27357 TO ITERATE

100.0% PROCESSED 27357 ITERATIONS 157 ANSWERS
SEARCH TIME: 00.00.01

L6 157 SEA SSS FUL L4

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 325.45

FILE 'CAPLUS' ENTERED AT 13:45:08 ON 20 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 May 2005 VOL 142 ISS 22
FILE LAST UPDATED: 19 May 2005 (20050519/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L6
L7 7 L6

=> d ibib abs hitstr 1-7

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:390231 CAPLUS
DOCUMENT NUMBER: 140:391196
TITLE: Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
INVENTOR(S): Caron, Stephane; Ghosh, Arun; Sieser, Janice Ethel
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039785	A1	20040513	WO 2003-IB4676	20031022

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004152896 A1 20040805 US 2003-699106 20031031
PRIORITY APPLN. INFO.: US 2002-423328P P 20021101
OTHER SOURCE(S): MARPAT 140:391196
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a new process for the preparation of the well-known kappa agonists I via a copper salt-catalyzed amination of an oxazolidinone II with an aryl halide III in the presence of an amino ligand and a base [wherein A = H, OH and derivs., fluoro/alkyl, etc.; Ar1 = (un)substituted phenyl; Ar2 = (un)substituted Ph, naphthyl, pyridinyl, thiophenyl, furyl, pyrrolyl, pyrimidinyl; R1 = alkyl, benzyl, with its Ph part optionally substituted; R2, R3 = independently H, (un)substituted alkyl, or R2R3N = (un)substituted pyrrolidine, piperidine, morpholine; X = Cl, Br, I]. The advantages of the aryl amination include high yields, mild, efficient, cost-effective and robust process. For example, aryl amination of S-(+)-4-phenyloxazolidin-2-one with 4-bromo-N-propylbenzamide in the presence of CuI/K2CO3 gave the intermediate IV, used in the synthesis of pyrrolidinyl ethylamine V.

IT **686347-77-3P**, Benzoic acid 1-[2-[methyl[4-(propylcarbamoyl)phenyl]amino]-2-phenylethyl]pyrrolidin-3-yl ester
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(amine product; process for preparation of pyrrolidinyl ethylamines via a copper-mediated aryl amination)

RN 686347-77-3 CAPLUS

CN Benzamide, 4-[[2-[3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)



IT **686347-76-2P**, Benzoic acid 1-[2-phenyl-2-[[4-(propylcarbamoyl)phenyl]amino]ethyl]pyrrolidin-3-yl ester

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of pyrrolidinyl ethylamines via a copper-mediated aryl amination)

RN 686347-76-2 CAPLUS

CN Benzamide, 4-[[2-[3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:877272 CAPLUS

DOCUMENT NUMBER: 140:111217

TITLE: Efficient synthesis of the κ-opioid receptor agonist CJ-15,161: four stereospecific inversions at a single aziridinium stereogenic center

AUTHOR(S): Couturier, Michel; Tucker, John L.; Andresen, Brian M.; DeVries, Keith M.; Vanderplas, Brian C.; Ito, Fumitaka

CORPORATE SOURCE: Chemical Research & Development, Pfizer Inc., Groton, CT, 06340, USA

SOURCE: Tetrahedron: Asymmetry (2003), 14(22), 3517-3523
CODEN: TASYE3; ISSN: 0957-4166

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:111217

GI



I

AB An efficient four-step sequence has been developed for the synthesis of the κ-opioid receptor agonist I (CJ-15,161). The process features four consecutive regioselective and stereospecific inversions at a single aziridinium stereogenic center, which leads to overall retention of stereochem., in a single operation. The chemical is straightforward, practical and amenable to large-scale synthesis. Crystal structure of suitable for formulation polymorph benzoate salt form of I is also reported.

IT **646041-98-7**
RL: PRP (Properties)
(crystal structure; large-scale synthesis of κ-opioid receptor agonist, (arylamino)(phenyl)ethyl pyrrolidinol)

RN 646041-98-7 CAPLUS

CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl-, monobenzoate (salt), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 204970-97-8
CMF C23 H31 N3 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 65-85-0
CMF C7 H6 O2



IT **473916-34-6P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(large-scale synthesis of κ-opioid receptor agonist, (arylamino)(phenyl)ethyl pyrrolidinol)

RN 473916-34-6 CAPLUS

CN Benzamide, 4-[[(1S)-2-[(3S)-3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **204970-97-8P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(large-scale synthesis of κ-opioid receptor agonist, (arylamino)(phenyl)ethyl pyrrolidinol)
RN 204970-97-8 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:696867 CAPLUS
DOCUMENT NUMBER: 139:230618
TITLE: Preparation of crystalline anhydrous and monohydrate benzoate salts of (2'S,3S)-3-hydroxy-N-[2-[N-methyl-N-4-[(N-propylamino)carbonyl]phenyl]amino-2-phenyl]ethylpyrrolidine as κ-opioid receptor agonists
INVENTOR(S): Quallich, George Joseph; Castaldi, Michael James
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

after PRV date

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072544	A1	20030904	WO 2003-IB560	20030217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477634	AA	20030904	CA 2003-2477634	20030217
EP 1478622	A1	20041124	EP 2003-742880	20030217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008052	A	20041228	BR 2003-8052	20030217
US 2004235936	A1	20041125	US 2003-421209	20030423
PRIORITY APPLN. INFO.:			US 2002-360250P	P 20020228
			WO 2003-IB560	W 20030217

GI



I

AB A process for preparing an anhydrous crystalline benzoate salt of (2'S,3S)-3-hydroxy-N-[2-[N-methyl-N-4-[(N-propylamino)carbonyl]phenyl]amino-2-phenyl]ethylpyrrolidine (I) and the corresponding I crystalline benzoate monohydrate is described which comprises: salifying (2'S,3S)-3-hydroxy-N-[2-[N-methyl-N-4-[(N-propylamino)carbonyl]phenyl]amino-2-phenyl]ethylpyrrolidine with benzoic acid in the presence of an alkyl alc. (e.g., 2-propanol), and isolating the anhydrous I salt (X-ray diffraction data is presented). The crystalline monohydrate benzoate salt of (2'S,3S)-3-hydroxy-N-[2-[N-methyl-N-4-[(N-propylamino)carbonyl]phenyl]amino-2-phenyl]ethylpyrrolidine is prepared by: treating anhydrous I with an aqueous alkanol solution; and isolating the crystallization I monohydrate (X-ray diffraction data is presented). These benzoate salts are selective kappa-receptor agonists, and are useful as analgesics, anesthetics, anti-inflammatory or neuroprotective agents, or in the treatment of arthritis, stroke or functional bowel disease (all no data).

IT **591769-11-8P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of crystalline anhydrous and monohydrate benzoate salts of (2'S,3S)-3-hydroxy-N-[2-[N-methyl-N-4-[(N-propylamino)carbonyl]phenyl]amino-2-phenyl]ethylpyrrolidine as κ-opioid receptor agonists)

RN 591769-11-8 CAPLUS

CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl-, compd. with phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 204970-97-8
CMF C23 H31 N3 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 108-95-2
CMF C6 H6 O



IT **591769-12-9P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline anhydrous and monohydrate benzoate salts of (2'S,3S)-3-hydroxy-N-[2-[N-methyl-N-4-[(N-propylamino)carbonyl]phenyl]amino-2-phenyl]ethylpyrrolidine as κ-opioid receptor agonists)
RN 591769-12-9 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl-, compd. with phenol (1:1), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 204970-97-8
CMF C23 H31 N3 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 108-95-2
CMF C6 H6 O



IT **204970-97-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of crystalline anhydrous and monohydrate benzoate salts of (2'S,3S)-3-hydroxy-N-[2-[N-methyl-N-4-[(N-propylamino)carbonyl]phenyl]amino-2-phenyl]ethylpyrrolidine as κ-opioid receptor agonists)
RN 204970-97-8 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:833565 CAPLUS
DOCUMENT NUMBER: 137:337777

TITLE: Preparation of hydroxypyrrolidinyl ethylamine compounds useful as selective κ-opioid receptor agonists

INVENTOR(S): Devries, Keith M.; Couturier, Michel A.; Andresen, Brian M.; Tucker, John L.; Ito, Fumitaka

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161241	A1	20021031	US 2002-133954	20020426
US 6624313	B2	20030923		
CA 2445874	AA	20021107	CA 2002-2445874	20020325
WO 2002088082	A2	20021107	WO 2002-IB924	20020325
WO 2002088082	A3	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2002009270	A	20040615	BR 2002-9270	20020325
EP 1461317	A2	20040929	EP 2002-716961	20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005508851	T2	20050407	JP 2002-585384	20020325

PRIORITY APPLN. INFO.:	US 2001-287428P	P	20010430
	US 2001-314006P	P	20010821
	WO 2002-IB924	W	20020325

OTHER SOURCE(S): CASREACT 137:337777; MARPAT 137:337777

GI



I

AB Hydroxypyrrolidinyl ethylamine compds. [I; wherein R1 = H, OH, (C1-C4)alkyl, (C1-C4)alkoxy, etc.; R2, R3, independently = H, (C1-C4)alkyl; Ar1, Ar2, independently = aryl, and particularly phenyl] were prepared For example, (2'S,3S)-3-benzoyloxy-N-{2-[N-methyl-N-4-(N-propylaminocarbonyl)phenyl]amino-2-phenyl}ethylpyrrolidine was prepared by a multistep synthetic procedure. The compds. are useful as selective κ-opioid receptor agonists. In fact, some of the title compds. showed a potent IC50 value against kappa-receptor in the range of 0.01 to 100 nM.

IT **204970-97-8P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)
(preparation of hydroxypyrrolidinyl ethylamine compds. useful as selective κ-opioid receptor agonists)

RN 204970-97-8 CAPLUS

CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **473916-34-6P**

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxypyrrolidinyl ethylamine compds. useful as selective κ-opioid receptor agonists)

RN 473916-34-6 CAPLUS

CN Benzamide, 4-[[(1S)-2-[(3S)-3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:517323 CAPLUS

DOCUMENT NUMBER: 138:73134

TITLE: Synthesis of the kappa-agonist CJ-15,161 via a palladium-catalyzed cross-coupling reaction

AUTHOR(S): Ghosh, Arun; Sieser, Janice E.; Caron, Stephane; Watson, Timothy J. N.

CORPORATE SOURCE: Chemical Research and Development, Pfizer Global Research and Development, Groton, CT, 06340-8013, USA

SOURCE: Chemical Communications (Cambridge, United Kingdom) (2002), (15), 1644-1645

CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:73134

AB Syntheses of CJ-15,161 involving intermol. N-arylation of an appropriately functionalized diamine, obtained from the precursor α-amino acids or, more conveniently, from the corresponding 1,2-amino alcs. via 1,2,3-oxathiazolidine-2,2-dioxide, are reported.

IT **479687-38-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(formylation of; preparation of kappa-agonist compound via palladium-catalyzed
cross-coupling reactions)

RN 479687-38-2 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]amino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **473916-34-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(hydrolysis of; preparation of kappa-agonist compound via palladium-catalyzed
cross-coupling reactions)

RN 473916-34-6 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-(benzoyloxy)-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **204970-97-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of kappa-agonist compound via palladium-catalyzed cross-coupling
reactions)
RN 204970-97-8 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:178439 CAPLUS
DOCUMENT NUMBER: 134:222619
TITLE: Preparation of pyrrolidinyl- and pyrrolinylethylarylamines as kappa opioid receptor agonists
INVENTOR(S): Ito, Fumitaka; Kondo, Hiroshi
PATENT ASSIGNEE(S): Pfizer, Inc., USA
SOURCE: U.S., 39 pp., Cont.-in-part of Appl. No. PCT/IB96/00957.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6201007	B1	20010313	US 1999-254805	19990312
WO 9812177	A1	19980326	WO 1997-IB1021	19970821
W: AU, BG, BR, CA, CN, CZ, HU, IL, IS, JP, KR, LK, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 2001316344	A2	20011113	JP 2001-92342	19970821
US 2001008890	A1	20010719	US 2001-770515	20010126
US 6310061	B2	20011030		
US 2001009921	A1	20010726	US 2001-770513	20010126
US 6313302	B2	20011106		
US 2001011091	A1	20010802	US 2001-770514	20010126
US 6294569	B2	20010925		
US 2001014683	A1	20010816	US 2001-771029	20010126

cited in Spec. discloses compound

US 6307061	B2	20011023			
US 2001020024	A1	20010906	US 2001-771030		20010126
US 6294557	B2	20010925			
US 6303602	B1	20011016	US 2001-770512		20010126
PRIORITY APPLN. INFO.:			WO 1996-IB957	A2	19960918
			WO 1997-IB1021	W	19970821
			JP 1998-514433	A3	19970821
			US 1999-254805	A3	19990312

OTHER SOURCE(S): MARPAT 134:222619

GI



I

AB Title compds. [I; A = H, halo, OH, alkyl, haloalkyl, alkoxy, haloalkoxy, O, OY, null; Y = protecting group; broken line = optional double bond; Ar1 = (substituted) Ph; Ar2 = (substituted) Ph, naphththyl, pyridyl, thienyl, furyl, pyrrolyl, pyrimidinyl; R1 = H, OH, alkyl, alkoxy, OY; and R2, R3 = (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, Ph, etc.; R2R3N = (substituted) pyrrolidinyl, piperidinyl, morpholinyl], were prepared as κ agonists (no data). Thus, a mixture of 2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol, 2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol (preparation given), and Et3N in CH2Cl2 was treated with MeSO2Cl at 0° followed by 5,5 h stirring at room temperature to give a residue which was refluxed 1.5 h with Me 4-methylaminobenzoate in EtOH to give 62.5% Me 4-[N-[2-(3(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino]benzoate. This was saponified with NaOH in MeOH (quant.) and the acid was stirred with PrNH2 and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 to give 72% Me 4-[N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino]-N'-propylbenzamide.

IT **204970-97-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrrolidinyl- and pyrrolinylethylarylamines as kappa opioid receptor agonists)

RN 204970-97-8 CAPLUS

CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 204970-95-6P 204970-99-0P 204971-01-7P
204971-03-9P 204971-05-1P 204971-07-3P
204971-09-5P 204971-11-9P 204971-13-1P
204971-15-3P 204971-17-5P 204971-19-7P
204971-21-1P 204971-23-3P 204971-25-5P
204971-27-7P 204971-29-9P 204971-30-2P
204971-32-4P 204971-34-6P 204971-36-8P
204971-38-0P 204971-40-4P 204971-42-6P
204971-44-8P 204971-46-0P 204971-48-2P
204971-50-6P 204971-52-8P 204971-54-0P
204971-56-2P 204971-58-4P 204971-61-9P
204971-62-0P 204971-64-2P 204971-66-4P
204971-67-5P 204971-68-6P 204971-69-7P
204971-70-0P 204971-71-1P 204971-72-2P
204971-73-3P 204971-75-5P 204971-76-6P
204971-77-7P 204971-78-8P 204971-79-9P
204971-80-2P 204971-82-4P 204971-83-5P
204971-86-8P 204971-87-9P 204971-89-1P
204971-90-4P 204971-91-5P 204971-92-6P
204971-93-7P 204971-94-8P 204971-95-9P
204971-96-0P 204971-97-1P 204972-01-0P
204972-02-1P 204972-03-2P 204972-07-6P
204972-08-7P 204972-09-8P 204972-10-1P
204972-11-2P 204972-12-3P 204972-13-4P
204972-14-5P 204972-15-6P 204972-16-7P
204972-17-8P 204972-18-9P 204972-19-0P
204972-20-3P 204972-21-4P 204972-22-5P
204972-23-6P 204972-24-7P 204972-25-8P
204972-26-9P 204972-27-0P 204972-28-1P
204972-29-2P 204972-30-5P 204972-31-6P
204972-32-7P 204972-33-8P 204972-34-9P
204972-35-0P 204972-36-1P 204972-37-2P
204972-38-3P 204972-39-4P 204972-40-7P
204972-41-8P 204972-42-9P 204972-43-0P
204972-44-1P 204972-45-2P 204972-46-3P
204972-47-4P 204972-48-5P 204972-49-6P
204972-50-9P 204972-51-0P 204972-52-1P
204972-53-2P 204972-54-3P 204972-56-5P
204972-57-6P 204972-58-7P 204972-59-8P
204972-60-1P 204972-61-2P 204972-62-3P
204972-63-4P 204972-66-7P 204972-67-8P
204972-68-9P 204972-69-0P 204972-70-3P
204972-71-4P 204972-72-5P 204972-73-6P
204972-74-7P 204972-75-8P 204972-76-9P
204972-77-0P 204973-49-9P 204973-55-7P
204973-56-8P 204995-07-3P 329365-40-4P

329365-41-5P 329365-43-7P 329365-44-8P
329365-45-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidinyl- and pyrrolinylethylarylamines as kappa opioid receptor agonists)

RN 204970-95-6 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-(methoxymethoxy)-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204970-99-0 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 204971-01-7 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-(methoxymethoxy)-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204971-03-9 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204971-05-1 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl



● HCl

RN 204973-57-9 CAPLUS
CN Acetic acid, [3-[2-[3-(methoxymethoxy)-1-pyrrolidinyl]-1-[methyl[4-[(propylamino)carbonyl]phenyl]amino]ethyl]phenoxy]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204995-07-3 CAPLUS
CN Benzamide, 4-[[(1S)-2-[(3S)-3-(methoxymethoxy)-1-pyrrolidinyl]-1-phenylethyl]methylamino]-N-(2,2,3,3,3-pentafluoropropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil casreact

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.48	360.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.11	-5.11

FILE 'CASREACT' ENTERED AT 13:46:34 ON 20 MAY 2005

FILE CONTENT:1840 - 15 May 2005 VOL 142 ISS 20

New CAS Information Use Policies, enter HELP USAGETERMS for details.

****
*
* CASREACT now has more than 9.2 million reactions *
*
****

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:40:22 ON 20 MAY 2005)

FILE 'REGISTRY' ENTERED AT 13:40:29 ON 20 MAY 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL

```
     FILE 'REGISTRY' ENTERED AT 13:44:38 ON 20 MAY 2005
L4                STRUCTURE UPLOADED
L5              7 S L4
L6            157 S L4 FULL

     FILE 'CAPLUS' ENTERED AT 13:45:08 ON 20 MAY 2005
L7              7 S L6

     FILE 'CASREACT' ENTERED AT 13:46:34 ON 20 MAY 2005

=> s L7(L)(copper or cuprous or cupric)
              3 L6
          14251 COPPER
             14 COPPERS
          14252 COPPER
                  (COPPER OR COPPERS)
           2473 CUPROUS
           1898 CUPRIC
L8            0 L7(L)(COPPER OR CUPROUS OR CUPRIC)

=> s L7 and copper
              3 L6
          14251 COPPER
             14 COPPERS
          14252 COPPER
                  (COPPER OR COPPERS)
L9            0 L7 AND COPPER

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    62.99     423.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -5.11

FILE 'CAPLUS' ENTERED AT 13:48:18 ON 20 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 May 2005  VOL 142 ISS 22
FILE LAST UPDATED: 19 May 2005  (20050519/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s L7(L)(copper or cuprous or cupric)
```

CASREACT

```
        843486 COPPER
           423 COPPERS
        843550 COPPER
                  (COPPER OR COPPERS)
         19174 CUPROUS
         27858 CUPRIC
L10           1 L7(L)(COPPER OR CUPROUS OR CUPRIC)

=> d L10

L10 ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:390231  CAPLUS
DN   140:391196
TI   Process for the preparation of pyrrolidinyl ethylamine compounds via a
     copper-mediated aryl amination
IN   Caron, Stephane; Ghosh, Arun; Sieser, Janice Ethel
PA   Pfizer Products Inc., USA
SO   PCT Int. Appl., 34 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2004039785         A1    20040513    WO 2003-IB4676          20031022
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004152896          A1    20040805    US 2003-699106          20031031
PRAI US 2002-423328P        P     20021101
OS   MARPAT 140:391196


=> s L7 and copper
        843486 COPPER
           423 COPPERS
        843550 COPPER
                  (COPPER OR COPPERS)
L11           1 L7 AND COPPER

=> d L11

L11 ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:390231  CAPLUS
DN   140:391196
TI   Process for the preparation of pyrrolidinyl ethylamine compounds via a
     copper-mediated aryl amination
IN   Caron, Stephane; Ghosh, Arun; Sieser, Janice Ethel
PA   Pfizer Products Inc., USA
SO   PCT Int. Appl., 34 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
```

```
PI   WO 2004039785          A1     20040513    WO 2003-IB4676          20031022
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004152896          A1     20040805    US 2003-699106          20031031
PRAI US 2002-423328P        P      20021101
OS   MARPAT 140:391196


=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                     10.21      434.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                      0.00       -5.11

STN INTERNATIONAL LOGOFF AT 13:48:50 ON 20 MAY 2005
```